Reynald Castañeda is a deputy editor at Endpoints News. With a decade of journalism experience, he specializes in medicine and healthcare, focusing on pharmaceutical manufacturing, regulation, and healthcare administration. His insightful reporting has been featured in Yahoo Finance, NewsBreak, and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Reynald Castaneda's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly pharmaceutical companies' developments, mergers & acquisitions, drug development, clinical trials. His articles often include press releases and cited data.
To effectively reach out to Reynald, consider providing detailed insights into newsworthy scientific advancements in drug development or clinical trial results. Additionally, if you have expertise related to mergers and acquisitions within the pharmaceutical industry or can provide valuable analysis of healthcare-related data trends, it could be of interest to him.
As his geographic focus is not specified but given that many news items are international in scope with global pharma companies involved, pitching internationally relevant content would likely align best with his coverage areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Reynald Castañeda
Neurocrine Biosciences said that a candidate for major depressive disorder that it got from Takeda did not succeed in a mid-stage trial.
By: Reynald Castañeda
Deputy Editor Merck said Friday it is buying Cidara Therapeutics in a deal worth $9.2 billion, centered around the biotech's late-stage preventive antiviral biologic for seasonal influenza …
By: Reynald Castañeda, Ayisha Sharma, Anna Brown
Deputy Editor News Reporter News Reporter LONDON – Jefferies Healthcare Conference may have found its groove.
By: Reynald Castaneda
A year after it reported a Phase 2/3 hit, Compass Therapeutics on Monday revealed further results for its bispecific antibody in second-line biliary tract cancer.
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test by year’s end.
By: Reynald Castaneda
Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase …
By: Reynald Castaneda
Eli Lilly, which has made billions off of the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront in a global pact for a GLP-2 analog called sonefpeglutide. The Seoul-based biotech could receive up to $1.185 billion in R&D, regulatory and sales milestone payments, on top of potential royalties.
By: Reynald Castaneda
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered 'landmark' results, and the drug's safety profile has previously been one of its main potential selling points. But Wall Street was rattled by malignancy events that call this into question.
By: Reynald Castaneda
ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial.
By: Reynald Castaneda
Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.
